Concert Pharmaceuticals Inc Quick Ratio (CNCE) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Concert Pharmaceuticals Inc   (NASDAQ: CNCE)

Concert Pharmaceuticals Inc 's Quick Ratio

CNCE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 5.51 below Concert Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 271 other companies have achieved higher Quick Ratio than Concert Pharmaceuticals Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 753 to 865.

Explain Quick Ratio?
How much Cash & cash equivalents CNCE´s has?
What are CNCE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNCE Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 44.74 % 86.39 % 81.65 % 58.38 % 63.13 %
Y / Y Cash & cash equivalent Change -9.75 % 12.21 % -35.22 % 80.75 % 189.98 %
Quick Ratio MRQ 5.51 8.67 4 8.88 8.84
CNCE's Total Ranking # 865 # 753 # 1108 # 244 # 558
Seq. Current Liabilities Change 7.67 % 7.15 % -6.44 % 34.1 % 38.65 %
Seq. Cash & cash equivalent Change -31.57 % 132.46 % -57.89 % 34.72 % -14.92 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 272
Healthcare Sector # 450
Overall Market # 865


Quick Ratio Statistics
High Average Low
31.52 10.62 2.82
(Dec 31 2017)   (Sep 30 2019)




Financial Statements
Concert Pharmaceuticals Inc 's Current Liabilities $ 17 Millions Visit CNCE's Balance sheet
Concert Pharmaceuticals Inc 's Cash & cash equivalent $ 96 Millions Visit CNCE's Balance sheet
Source of CNCE's Sales Visit CNCE's Sales by Geography


Cumulative Concert Pharmaceuticals Inc 's Quick Ratio

CNCE's Quick Ratio for the trailling 12 Months

CNCE Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 65.32 % 72.02 % 46.31 % 8.88 % -19.28 %
Y / Y Cash & cash equivalent TTM Growth 8.94 % 34.76 % 82.07 % 140.02 % 131.9 %
Quick Ratio TTM 6.78 7.57 8.37 10.36 10.29
Total Ranking TTM # 4124 # 4073 # 529 # 266 # 3919
Seq. Current Liabilities TTM Growth 9.06 % 14.43 % 15.03 % 15.17 % 13.48 %
Seq. Cash & cash equivalent TTM Growth -2.3 % 3.51 % -7.01 % 15.85 % 20.86 %

Quick ratio ranking by company, industry and sector >> Back to CNCE Financial Strength Comparisons >> Go to Compare CNCE Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2022 to $17.40 millions, cumulative Quick Ratio decreased to 6.78 below the Concert Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 569 other companies have achieved higher Quick Ratio than Concert Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 4073 to 4124.

Explain Quick Ratio?
How much Cash & cash equivalents CNCE´s has?
What are CNCE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 570
Healthcare Sector # 1127
Within the Market # 4124


trailing twelve months Quick Ratio Statistics
High Average Low
23.88 11.31 3.21
(Dec 31 2017)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Fulcrum Therapeutics Inc   15.09 $ 221.789  Millions$ 14.699  Millions
Crinetics Pharmaceuticals Inc   15.00 $ 368.362  Millions$ 24.556  Millions
Nkarta Inc   14.85 $ 392.356  Millions$ 26.425  Millions
Akero Therapeutics Inc   14.82 $ 374.003  Millions$ 25.243  Millions
Pds Biotechnology Corp  14.80 $ 71.642  Millions$ 4.841  Millions
Protagenic Therapeutics Inc new  14.73 $ 8.153  Millions$ 0.554  Millions
Oric Pharmaceuticals Inc   14.58 $ 193.659  Millions$ 13.284  Millions
Cytokinetics Incorporated  14.36 $ 867.664  Millions$ 60.440  Millions
Cryoport inc   14.31 $ 530.451  Millions$ 37.076  Millions
Lianbio  14.15 $ 311.728  Millions$ 22.027  Millions
Gyre Therapeutics Inc   14.05 $ 23.090  Millions$ 1.644  Millions
Sage Therapeutics Inc   13.98 $ 1,393.639  Millions$ 99.687  Millions
Pliant Therapeutics Inc   13.77 $ 360.241  Millions$ 26.161  Millions
Sensei Biotherapeutics Inc   13.73 $ 116.558  Millions$ 8.492  Millions
Rani Therapeutics Holdings Inc   13.66 $ 98.171  Millions$ 7.186  Millions
Lumos Pharma Inc   13.44 $ 73.666  Millions$ 5.483  Millions
Annexon Inc   13.33 $ 269.519  Millions$ 20.220  Millions
Larimar Therapeutics Inc   13.24 $ 124.699  Millions$ 9.420  Millions
Liquidia Corporation  13.18 $ 98.320  Millions$ 7.460  Millions
Xenetic Biosciences Inc   13.18 $ 13.848  Millions$ 1.051  Millions
Psyence Biomedical ltd   13.05 $ 0.605  Millions$ 0.046  Millions
Aclaris Therapeutics Inc   13.04 $ 248.062  Millions$ 19.023  Millions
Iveric Bio Inc   13.04 $ 320.535  Millions$ 24.588  Millions
Erasca Inc   12.86 $ 355.928  Millions$ 27.679  Millions
Arcutis Biotherapeutics Inc   12.86 $ 476.963  Millions$ 37.102  Millions
Kronos Bio Inc   12.85 $ 258.255  Millions$ 20.105  Millions
Verrica Pharmaceuticals Inc   12.82 $ 39.454  Millions$ 3.078  Millions
Lyell Immunopharma Inc   12.65 $ 648.132  Millions$ 51.217  Millions
Pepgen Inc   12.62 $ 195.783  Millions$ 15.519  Millions
Calcimedica Inc   12.61 $ 43.627  Millions$ 3.460  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.